Effect on impact properties of adding tantalum to V-4Cr-4Ti ternary vanadium alloy

Four V-Ta-4Cr-4Ti quaternary alloys containing different quantities of Ta were investigated to determine the effect of Ta content on the Charpy impact properties. Five button-shaped ingots of the V-4Cr-4Ti ternary alloy and V-xTa-4Cr-4Ti quaternary alloys (x = 3, 9, 15, and 22 wt.%) were fabricated on a laboratory scale by using non-consumable arc-melting in an argon atmosphere. Charpy impact tests were conducted at temperatures ranging from 77 K to 293 K using an instrumented impact tester. Both the upper shelf energy and the ductile–brittle transition temperature increased with increasing Ta content. The addition of 3 wt.% Ta resulted in solid solution strengthening without any degradation of the Charpy impact properties. Thus, the addition of 3 wt.% Ta (V-3Ta-4Cr-4Ti) is an appropriate amount to use in blanket structural materials for nuclear fusion reactors. The spectra of TEM-EDS for V-3Ta-4Cr-4Ti quaternary alloy indicate that there is no significant enrichment of Ta in the matrix as compared with that in the precipitate. However, thermal aging may result in the formation of the Laves phase, causing the degradation of Charpy impact properties. The characterization of precipitates, thermal aging, and creep tests of the V-3Ta-4Cr-4Ti quaternary alloy need to be investigated to determine the optimum Ta content

Current-Driven Domain Wall Dynamics in Ferrimagnetic Nickel-Doped Mn4N Films: Very Large Domain Wall Velocities and Reversal of Motion Direction across the Magnetic Compensation Point

International audienc

Cryptotanshinone is a candidate therapeutic agent for interstitial lung disease associated with a BRICHOS-domain mutation of SFTPC

Summary: Interstitial lung disease (ILD) represents a large group of diseases characterized by chronic inflammation and fibrosis of the lungs, for which therapeutic options are limited. Among several causative genes of familial ILD with autosomal dominant inheritance, the mutations in the BRICHOS domain of SFTPC cause protein accumulation and endoplasmic reticulum stress by misfolding its proprotein. Through a screening system using these two phenotypes in HEK293 cells and evaluation using alveolar epithelial type 2 (AT2) cells differentiated from patient-derived induced pluripotent stem cells (iPSCs), we identified Cryptotanshinone (CPT) as a potential therapeutic agent for ILD. CPT decreased cell death induced by mutant SFTPC overexpression in A549 and HEK293 cells and ameliorated the bleomycin-induced contraction of the matrix in fibroblast-dependent alveolar organoids derived from iPSCs with SFTPC mutation. CPT and this screening strategy can apply to abnormal protein-folding-associated ILD and other protein-misfolding diseases